Akero Therapeutics, Inc.

    Jurisdiction
    United States
    LEI
    549300SI3KG74LBE2955
    ISIN
    US00973Y1082 (AKRO)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 44 / 100
    Worse than peer group:
    48 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€275.83M
    EBIT margin
    0.0%
    Net income
    -€243.64M
    Net margin
    0.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A -€299.60M +23.0%
    N/A -€344.02M +14.8%
    €117.87M -€207.19M -39.8%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Young Jonathan Chief Operating Officer -13K $46.08 -$576.00K
    Henderson Jane N/A -3K $47.46 -$142.38K
    Young Jonathan Chief Operating Officer -13K $47.79 -$597.38K
    Cheng Andrew President and CEO -30K $48.59 -$1.46M
    Rolph Timothy Chief Scientific Officer -13K $49.30 -$616.25K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 199K $8.06M +178K Buy

    Add to watchlist

    Notifications